https://charts.traderzeitung.de/phases/US12529R1077
string(1389) "{"isin":"US12529R1077","name":"C4 Therapeutics Inc","stock_id":15155021,"generated_at":"2026-10-29 00:57:00","days":[{"date":"2026-10-26","dst_offset":5,"phases":[{"phase":1,"label":"pre","from":"09:00","to":"14:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"14:30","to":"21:00","close":2.975,"close_at":"2026-10-26 20:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"21:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-27","dst_offset":5,"phases":[{"phase":1,"label":"pre","from":"09:00","to":"14:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"14:30","to":"21:00","close":3.225,"close_at":"2026-10-27 20:59:00","complete":true,"perf_pct":8.4034},{"phase":3,"label":"post","from":"21:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-28","dst_offset":5,"phases":[{"phase":1,"label":"pre","from":"09:00","to":"14:30","close":3.29,"close_at":"2026-10-28 12:43:00","complete":true,"perf_pct":2.0155},{"phase":2,"label":"regular","from":"14:30","to":"21:00","close":3.39,"close_at":"2026-10-28 20:59:00","complete":true,"perf_pct":3.0395},{"phase":3,"label":"post","from":"21:00","to":"26:00","close":null,"close_at":null,"complete":false,"perf_pct":null}]}]}"
array (
'data' =>
array (
'isin' => 'US12529R1077',
'name' => 'C4 Therapeutics Inc',
'stock_id' => 15155021,
'generated_at' => '2026-10-29 00:57:00',
'days' =>
array (
0 =>
array (
'date' => '2026-10-26',
'dst_offset' => 5,
'phases' =>
array (
0 =>
array (
'phase' => 1,
'label' => 'pre',
'from' => '09:00',
'to' => '14:30',
'close' => NULL,
'close_at' => NULL,
'complete' => true,
'perf_pct' => NULL,
),
1 =>
array (
'phase' => 2,
'label' => 'regular',
'from' => '14:30',
'to' => '21:00',
'close' => 2.975,
'close_at' => '2026-10-26 20:59:00',
'complete' => true,
'perf_pct' => NULL,
),
2 =>
array (
'phase' => 3,
'label' => 'post',
'from' => '21:00',
'to' => '26:00',
'close' => NULL,
'close_at' => NULL,
'complete' => true,
'perf_pct' => NULL,
),
),
),
1 =>
array (
'date' => '2026-10-27',
'dst_offset' => 5,
'phases' =>
array (
0 =>
array (
'phase' => 1,
'label' => 'pre',
'from' => '09:00',
'to' => '14:30',
'close' => NULL,
'close_at' => NULL,
'complete' => true,
'perf_pct' => NULL,
),
1 =>
array (
'phase' => 2,
'label' => 'regular',
'from' => '14:30',
'to' => '21:00',
'close' => 3.225,
'close_at' => '2026-10-27 20:59:00',
'complete' => true,
'perf_pct' => 8.4034,
),
2 =>
array (
'phase' => 3,
'label' => 'post',
'from' => '21:00',
'to' => '26:00',
'close' => NULL,
'close_at' => NULL,
'complete' => true,
'perf_pct' => NULL,
),
),
),
2 =>
array (
'date' => '2026-10-28',
'dst_offset' => 5,
'phases' =>
array (
0 =>
array (
'phase' => 1,
'label' => 'pre',
'from' => '09:00',
'to' => '14:30',
'close' => 3.29,
'close_at' => '2026-10-28 12:43:00',
'complete' => true,
'perf_pct' => 2.0155,
),
1 =>
array (
'phase' => 2,
'label' => 'regular',
'from' => '14:30',
'to' => '21:00',
'close' => 3.39,
'close_at' => '2026-10-28 20:59:00',
'complete' => true,
'perf_pct' => 3.0395,
),
2 =>
array (
'phase' => 3,
'label' => 'post',
'from' => '21:00',
'to' => '26:00',
'close' => NULL,
'close_at' => NULL,
'complete' => false,
'perf_pct' => NULL,
),
),
),
),
),
'success' => true,
)
C4 Therapeutics Aktie News & Nachrichten
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Artikel aus der Redaktion der Trader-Zeitung
28.10.2026 um 16 Uhr
C4 Therapeutics nutzt den gezielten Proteinabbau zur Krebsbehandlung und treibt die klinische Entwicklung...
